Daratumumab-based quadruplet therapy in functional high-risk relapse/refractory multiple myeloma patients induces changes associated with CD8 T cell signaling, activation and expansion

Analysis reveals enhanced CD8 T cell activation and expansion in functional high-risk myeloma patients following daratumumab therapy, suggesting implications for future treatment strategies.